Can Sustained Nicotinamide Delivery Help Heal Traumatic Brain Injury?
"New research explores how continuous nicotinamide infusion could revolutionize TBI recovery, offering hope for improved neurological outcomes."
Traumatic brain injury (TBI) is a significant public health issue, affecting millions worldwide. Despite advancements in medical care, effective treatments to aid recovery during the acute or secondary stages of TBI remain limited. This lack of treatment options highlights the urgent need for innovative therapeutic strategies.
A major challenge in TBI research is the translational gap: many therapeutic compounds show promise in preclinical studies but fail to deliver the same benefits in clinical trials. Factors contributing to this gap include differences in treatment windows and durations between laboratory experiments and real-world clinical scenarios. The study bridges the treatment gap by studying nicotinamide.
Recognizing this challenge, researchers have turned their attention to nicotinamide (NAM), a neuroprotective soluble B-group vitamin. Prior studies indicate NAM's potential to improve recovery after TBI. This article explores whether continuous NAM infusion over several days post-TBI could enhance recovery.
The Scale of TBI
The CDC describes traumatic brain injury (TBI) as a major cause of death and disability. Approximately 214,110 TBI-related hospitalizations occurred in the United States in 2020, and 68,663 TBI-related deaths occurred in 2023. The CDC also reports that more than 69,000 TBI-related deaths occurred in the United States in 2021, underscoring the condition's substantial public-health impact.
Evolving TBI Care
Current TBI management includes both traditional and alternative strategies, as summarized in a review of modern treatment approaches. TBI is increasingly understood not only as an acute condition but also as a chronic disease with long-term consequences, including an increased risk of late-onset neurodegeneration. Despite extensive research, TBI continues to impose a significant global mortality and morbidity burden, while classification, surgical care, critical care, and physiological treatment goals continue to evolve.
Nicotinamide (NAM) Improves Functional Recovery
Researchers at Southern Illinois University and the University of Washington investigated the effects of sustained nicotinamide (NAM) delivery on traumatic brain injury (TBI) recovery in rats. The study, published in Oxidative Medicine and Cellular Longevity, explored whether continuous NAM infusion could improve neurological outcomes compared to traditional bolus administrations.
- Improved Sensorimotor Function: Continuous NAM infusion significantly reduced initial injury deficits and enhanced overall recovery on tactile removal and locomotor placing tasks.
- Reduced Limb-Use Asymmetry: NAM treatment decreased the bias towards using the uninjured limb, promoting more balanced motor function.
- Limited Cortical Damage: NAM significantly reduced the extent of cortical damage compared to vehicle-treated animals.
- Elevated NAM Levels: The continuous infusion resulted in a significant increase in serum NAM levels, confirming effective drug delivery.
From Acute Injury to Lifelong Care
A 2025 review describes TBI research as reaching a turning point, with evidence that TBI can be a chronic condition characterized by prolonged biomarker elevations and long-term comorbidities. This perspective shifts clinical management from acute intervention toward lifelong monitoring and care. Recent reviews also examine both the primary biomechanics of injury and the molecular pathophysiology of the secondary injury cascade.
Limits of the Nicotinamide Evidence
In an experimental TBI study, continuous nicotinamide infusion produced a significant rise in serum nicotinamide but not NAD+. The researchers reported no overtly observable detrimental effects with continuous infusion and no detrimental effects in their experience with 50 or 500 mg/kg treatment. However, the study did not directly compare continuous infusion with bolus administration, so it could not determine whether sustained delivery was superior.
Management Depends on Context
Evidence comparing surgical and medical management in older adults with TBI remains limited, heterogeneous, and partly extrapolated from younger populations. A 2026 systematic review and meta-analysis addressed this uncertainty in a population associated with high mortality and poor functional outcomes. TBI also spans a spectrum from mild concussion to severe injury, while penetrating brain injury remains under-represented in evidence-based research.
Future Directions and Clinical Implications
This research provides a foundation for future studies aimed at optimizing NAM administration strategies for TBI. Further investigations could explore different NAM dosages, treatment durations, and administration windows to identify the most effective therapeutic protocol.
The Need for Multidisciplinary Judgment
TBI involves disruption of normal brain function caused by external forces such as blunt impact, acceleration-deceleration injury, or penetrating trauma. Expert analysis in TBI cases may require coordinated input across multiple clinical disciplines. Legal and clinical experts may review medical reports, analyze injury causes, explain the severity and long-term impact of brain injuries, and address rehabilitation requirements.
Precision and Personalization
Recent work describes the future management of TBI as moving toward greater precision, integration, and personalization. TBI remains a major cause of long-term neurological disability worldwide, ranging from minor injuries to severe forms with permanent impairment. Future projections in the Americas are being assessed using Global Burden of Disease 2023 estimates of incidence, prevalence, and years lived with disability.
Recovery Is Personal
TBI can produce motor, cognitive, emotional, and sensory impairments, as illustrated by Jake's patient story from Johns Hopkins Medicine. A longitudinal case study using pre-injury and post-injury 7 Tesla MRI found that trauma-related alterations in whole-brain connection density were markedly reduced at the final scan, consistent with symptom resolution. The Franklin Institute's case-study material also reports that, in a 2009 University of Michigan study commissioned by the NFL, 6 percent of retired NFL players over age 50 had been diagnosed with Alzheimer's disease, dementia, or another memory-related disease.
While this study highlights the potential benefits of sustained NAM delivery, it's important to acknowledge some limitations. The research was conducted in a rat model, and further studies are needed to confirm these findings in human populations. Additionally, the study focused on sensorimotor outcomes, and future research should investigate NAM's effects on cognitive and emotional recovery after TBI.
Despite these limitations, this research offers hope for improving TBI outcomes and underscores the importance of continued investigation into NAM's therapeutic potential.